Suberoylanilide hydroxamic acid
An article about Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor used in cancer treatment.
| Drug Information | |||
|---|---|---|---|
| Image | 
| ||
| Identifiers
|
Chemical Data
| ||
Suberoylanilide hydroxamic acid (SAHA), also known as vorinostat, is a histone deacetylase inhibitor (HDAC inhibitor) used in the treatment of cancer. It is primarily used for the treatment of cutaneous T-cell lymphoma (CTCL) and has shown potential in treating other types of cancer.
Mechanism of Action[edit | edit source]
Suberoylanilide hydroxamic acid works by inhibiting the activity of histone deacetylases. These enzymes are responsible for removing acetyl groups from histone proteins, which leads to a more compact and transcriptionally repressed chromatin structure. By inhibiting HDACs, SAHA causes an accumulation of acetylated histones, leading to a more open chromatin structure and increased transcription of genes that can induce cell cycle arrest, differentiation, and apoptosis in cancer cells.
Clinical Use[edit | edit source]
SAHA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent, or recurrent disease on or following two systemic therapies. It is administered orally and is typically used when other treatments have failed.
Side Effects[edit | edit source]
Common side effects of SAHA include fatigue, diarrhea, nausea, thrombocytopenia, and anorexia. More serious side effects can include pulmonary embolism, deep vein thrombosis, and dehydration. Patients undergoing treatment with SAHA require regular monitoring of blood counts and hydration status.
Research and Development[edit | edit source]
Research is ongoing to explore the efficacy of SAHA in treating other types of cancer, including breast cancer, prostate cancer, and non-small cell lung cancer. Studies are also investigating its potential use in combination with other anticancer agents to enhance therapeutic outcomes.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Bonnu, Prab R. Tumpati, MD
